Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | INCB106385 + Retifanlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB106385 | INCB-106385|INCB 106385 | Adenosine Targeting 22 | INCB106385 is a dual inhibitor of A2A and A2B receptors, which may prevent immune suppression in the tumor microenvironment and promote anti-tumor immune response (AACR Annual Meeting Apr 2020, Session PO.IM02.03, Abstract # LB157). | |
Retifanlimab | MGA 012|INCMGA00012|MGA012 | Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 | Retifanlimab (INCMGA00012) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | BEL | 1 |